Circulating type-1 anti-tumor CD4+ T cells are preferentially pro-apoptotic in cancer patients

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Wesa, Amy K ^a,b   Mandic, Maja ^a   Taylor, Jennifer L ^a   Moschos, Stergios ^a,c   Kirkwood, John M ^a,c   Kwok, William W ^d   Finke, James H ^e   Storkus, Walter J ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Peripheral blood; Tumor; Type 1

Indexed keywords

EPHRIN RECEPTOR A2; HLA DR4 ANTIGEN; MELANOMA ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; VERY ELDERLY;

EID: 84906242668     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00225     Document Type: Article

References (50)

1. Ali OA, Emerich D, DranoffG, Mooney DJ. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1:8ra19. doi: 10.1126/scitranslmed.3000359.
2. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol (2005) 174:3143-7.
3. + T cell efficacy in vaccination and disease. Nat Med (2008) 14:623-8. doi: 10.1038/nm.f.1774.
4. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T cell responses is mediated by CD40 signaling. Nature (1998) 393:478-80.
5. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 129:2158-70. doi: 10.1002/ijc.25863.
6. + T cell responses. Immunol Res (1998) 18:1-13.
7. Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother (2013) 36:248-57. doi:10.1097/CJI.0b013e3182943549.
8. + T cells that can be partially reversed by vaccination. J Clin Invest (2010) 120:157-67. doi: 10.1172/JCI40070.
9. + enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 16:6122-31. doi: 10.1158/1078-0432.CCR-10-1297.
10. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, et al. Interleukin-15/interleukin-15Ralpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res (2008) 68:2972-83. doi: 10.1158/0008-5472.CAN-08-0045.
11. + T cells from human immunodeficiency virus infected persons. J Exp Med (1995) 182:1759-67.
12. Finn OJ. Immuno-oncology: understanding the function a nd dysfunction of the immune system in cancer. Ann Oncol (2012) 23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256.
13. + T cell dysfunction in melanoma patients. J Exp Med (2010) 207:2175-86. doi: 10.1084/jem.20100637.
14. + T cells during recurrence of melanoma. J Immunol (2013) 190:4899-909. doi: 10.4049/jimmunol.1300271.
15. Gramenzi A, Andreone P, Loggi E, Foschi FG, Cursaro C, Margotti M, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat (2005) 12:525-30.
16. + T cell sequestration, dysfunction and deletion. Nat Med (2013) 19:465-72. doi: 10.1038/nm.3105.
17. Hamad AR, Schneck JP. Antigen-induced T cell death is regulated by CD4 expression. Int Rev Immunol (2001) 20:535-46.
18. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002 Aug;8(8):2553-62. PubMed PMID: 12171883.
19. + T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J Virol (2005) 79:6299-311.
20. + T lymphocytes. Nature (2003) 421:852-6.
21. Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines (2013) 12:285-95. doi: 10.1586/erv.13.22.
22. + T cells. Br J Cancer (2001) 85:1738-45.
23. + T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 10:5101-10.
24. Kim WU, Min SY, Hwang SH, Yoo SA, Kim KJ, Cho C S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol (2010) 161:453-8. doi: 10.1111/j.1365-2249.2010.04194.x.
25. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 15:2507-13. doi: 10.1158/1078-0432.CCR-08-2424.
26. Linnemann T, Jung G, Walden P. Detection and quantification of CD4+ T cells with specificity for a new major histocompatibility complex class II-restricted inFluenza A virus matrix protein epitope in peripheral blood of inFluenza patients. J Virol (2000) 74:8740-3.
27. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA (2004) 101 Suppl 2:14631-8.
28. Lu Y, Bocca S, Anderson S, Wang H, Manhua C, Beydoun H, et al. Modulation of the expression of the transcription factors T-bet and GATA-3 in immortalized human endometrial stromal cells (HESCs) by sex steroid hormones and cAMP. Reprod Sci (2013) 20:699-709. doi: 10.1177/1933719112466297.
29. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol (2000) 18:3782-93.
30. + T cells proliferating in response to inFluenza A antigen. J Clin Invest (1999) 104:R63-7.
31. + T lymphocytes: a critical component of antitumor immunity. Cancer Invest (2005) 23:413-9.
32. Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 15:500-8. doi: 10.1007/s11912-013-0337-1.
33. + T cells are susceptible to spontaneous apoptosis that can be inhibited by the chemokine CXCL12 and IL-2, -6, -7, and -15. Eur J Immunol (2004) 34:2771-80.
34. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 18:6758-70. doi: 10.1158/1078-0432.CCR-12-1177.
35. + T-helper and a T-killer cell. Nature (1998) 393:474-8.
36. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 10:909-15.
37. SaffRR, Spanjaard ES, Hohlbaum AM, Marshak-Rothstein A. Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J Immunol (2004) 172:6598-606.
38. + T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res (2000) 6:1351-64.
39. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 393:480-3.
40. Shirshev SV, Kuklina EM, Yarilin AA. Role of reproductive hormones in control of apoptosis of T-lymphocytes. Biochemistry (Mosc) (2003) 68:470-5.
41. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 100:655-69.
42. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res (2003a) 63:4481-9.
43. + patients with renal cell carcinoma or melanoma. J Exp Med (2002) 196:619-28.
44. + T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res (2003b) 9:947-54.
45. + T cells in healthy adults. J Virol (2013) 87:10263-72. doi: 10.1128/JVI.01540-13.
46. Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (2004) 173:1444-53.
47. Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMV-specific memory T helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol (2004) 65:476-85.
48. + T cells for accelerated suicide causes immune incompetence. J Clin Invest (2003) 111:1191-9.
49. + T lymphocytes. J Immunol (2009) 183:3720-30. doi: 10.4049/jimmunol.0900970.
50. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med (1997) 185:1837-49